Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 12/20 | 0.34 |
| ▸ | TK2 | O00142 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745666 | 0.87 | MAPT (0.32) | TK1MAPK1ALDH1A1 | |
| SCHEMBL6714052 | 0.72 | TK1 (0.57) | TK1TK2MAPK1HPGD | |
| SCHEMBL2559163 | 0.66 | KDM4E (0.50) | TK1KDM4E | |
| SCHEMBL31087986 | 0.66 | CYP1A2 (0.50) | TK1 | |
| SCHEMBL2745399 | 0.65 | ATAD2 (0.44) | HPGDKDM4EALDH1A1GAARAB9A | |
| SCHEMBL3562767 | 0.64 | LMNA (0.34) | TK1ALDH1A1 | |
| SCHEMBL3560818 | 0.63 | TK2 (0.38) | TK1TK2MAPK1HPGDALDH1A1 | |
| SCHEMBL2745191 | 0.62 | CYP2C9 (0.33) | TK1TK2MAPK1HPGDKDM4E | |
| SCHEMBL23873408 | 0.62 | LMNA (0.39) | TK1TK2 | |
| SCHEMBL16428045 | 0.62 | TK1 (0.35) | TK1TK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| WO-2009043883-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR5A, DRD5 | TK1 3555/4885TK2 4328/4885MAPK1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.